港股異動 | 李寧(2331.HK)高開4.05%創新高 旗下私募基金1億英鎊入主英鞋履品牌Clarks
格隆匯11月6日丨李寧(2331.HK)高開4.05%,報44.95港元續創歷史新高,暫成交1622萬港元,最新總市值1118億港元,該股今年迄今已累漲約94%。英國鞋履品牌Clarks同意以1億英鎊(約10億港元)向李寧創辦人李寧任主席的私募基金萊恩資本(LionRock Capital)出售多數股權,交易完成後,Clarks家族將保留少數股權。Clarks表示,萊恩資本將成為其最大的股東,其投資有助品牌在全球,尤其是在中國及亞太其他地區發展業務。摩通曾發研報指,調升李寧今年至2022年盈利預測2%至10%,將目標價上調至48.8港元,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.